The CH50 blood test measures the total functional activity of your classical complement pathway, a chain of proteins in your blood that helps your immune system destroy invaders and clear debris. Rather than checking for one specific protein, CH50 tells your doctor whether all nine major components of this pathway are present and working together. A result of zero, or one that falls well below the reference range, signals that at least one link in that chain is missing or severely depleted, while an elevated result can point toward active inflammation or tissue injury.
How the Test Actually Works
The CH50 assay is built around a surprisingly old-fashioned concept: watching blood burst open red blood cells in a tube. In the traditional version, a laboratory takes sheep red blood cells and coats them with an antibody that targets those cells. When your serum is added, the antibody-coated cells trigger the classical complement pathway, and if all the complement proteins are working, the cells rupture, releasing hemoglobin into the surrounding fluid. The lab measures how much hemoglobin is released and calculates the dilution of your serum needed to lyse exactly half the red blood cells, hence the “50” in CH50.1PubMed Central. Measuring the 50% haemolytic complement (CH50) activity of serum
This all-or-nothing quality is what makes the test useful as a screening tool. The classical pathway involves components labeled C1 through C9, and the cascade works sequentially. If any single component is completely absent, the cascade stalls and no hemolysis occurs, driving your CH50 to zero.1PubMed Central. Measuring the 50% haemolytic complement (CH50) activity of serum If a component is reduced rather than absent, the cascade still runs but less efficiently, producing a low but not zero result. That distinction between “zero” and “low” often shapes the next steps in a diagnostic workup.
What a Low CH50 Result Suggests
A low CH50 generally means complement proteins are being consumed faster than your body can replace them, or that you were born without enough of one or more of them. The most common clinical reason for low CH50 is autoimmune disease, and lupus is the textbook example. In lupus, immune complexes deposit in tissues and constantly activate the classical pathway, chewing through complement proteins. Levels of C3, C4, and total complement activity measured by CH50 all tend to drop during disease flares, and tracking these levels over time helps doctors gauge how active the disease is.2PubMed. Serological markers of disease activity in systemic lupus erythematosus Research on lupus patients has shown that the terminal complement complex in their blood runs inversely to CH50, meaning the more complement gets activated and consumed, the lower the CH50 reading falls.3PubMed Central. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases
Other autoimmune and inflammatory conditions can lower CH50 in a similar way. In ANCA-associated vasculitis, a disease involving blood vessel inflammation, researchers found that patients with lower CH50 values at diagnosis were more likely to have high disease activity than those with higher values.4PubMed Central. Total Haemolytic Complement Activity at Diagnosis as an Indicator of the Baseline Activity of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Any condition that generates a heavy load of immune complexes or directly damages tissues in a way that activates complement can theoretically drag CH50 down, including certain kidney diseases, severe infections, and some forms of liver disease, since the liver manufactures most complement proteins.
Inherited Complement Deficiencies
When CH50 comes back at zero or undetectable in a person who otherwise seems reasonably healthy, the suspicion shifts from consumption to a genetic deficiency. People born without a functional copy of one of the classical pathway components will have a CH50 that is permanently at or near zero, regardless of whether they are having a flare of anything. A study examining patients with confirmed genetic complement deficiencies found that those with homozygous mutations in C2 consistently had CH50 values below the lower normal limit, and those with homozygous C8 mutations had both CH50 and the alternative pathway equivalent (AH50) below normal.5PubMed Central. Functional Complement Analysis Can Predict Genetic Testing Results and Long-Term Outcome in Patients With Complement Deficiencies Carriers who had only one defective copy showed levels that were lower than average but still within or near the normal range, which is why a single borderline-low result does not automatically mean a genetic problem.
These inherited deficiencies matter beyond the laboratory number. People with congenital complement defects face a substantially higher risk of invasive infections caused by Neisseria bacteria, the family responsible for meningococcal meningitis and disseminated gonorrhea.6FEBS Letters. Complement interactions with the pathogenic Neisseriae: clinical features, deficiency states, and evasion mechanisms Neisseria are unusually dependent on complement for immune clearance, so a gap in the cascade gives these bacteria a much easier path. When a patient shows up with recurrent meningococcal infections or an unexplained episode at an unusual age, CH50 is one of the first tests ordered to check for an underlying complement deficiency.
What a High CH50 Can Mean
An elevated CH50 is less dramatic than a low one in most clinical settings, but it still carries information. Because complement proteins are produced in the liver and behave as acute-phase reactants, meaning their production ramps up during inflammation, CH50 can climb during active inflammatory conditions. Research on patients with acute venous thromboembolism found a significant rise in CH50 levels, though the study also suggested that the functional killing ability of complement may not keep pace with the protein increase, due to imbalances in the downstream cascade.7PubMed Central. Relationship of high CH50 level and interruption of cascade reaction of complement mRNA expression in acute venous thromboembolism patients
Elevated CH50 has also been documented in other inflammatory states. In a study comparing people with periodontitis (chronic gum disease) to healthy controls, both diabetic and non-diabetic patients with periodontitis showed higher CH50 than the control group, and the elevation was more pronounced in the diabetic patients.8PubMed Central. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of diabetic patients with periodontitis An isolated high CH50 usually does not trigger a major workup on its own, but when paired with other inflammatory markers, it adds to the clinical picture.
Pregnancy is another situation where CH50 naturally rises. Serum CH50 increases significantly during the second and third trimesters compared to non-pregnant women, which is part of the broader immunological shift that occurs during pregnancy.9PubMed. Serum complement levels in normal pregnancy and pregnancy-induced hypertension This means a mildly elevated CH50 in a pregnant patient does not necessarily signal a problem and needs to be interpreted in context.
How CH50 Fits into the Bigger Diagnostic Picture
Doctors rarely order CH50 by itself. It is almost always part of a complement panel that includes C3 and C4 levels, and sometimes AH50, which screens the alternative complement pathway the same way CH50 screens the classical one. The pattern of which tests are abnormal helps narrow the diagnosis. A low CH50 with low C3 and C4, for example, points toward heavy classical pathway consumption, which fits with lupus or immune complex disease. A low CH50 with normal C3 and low C4 might suggest a problem specific to the early part of the cascade. A CH50 of zero with normal individual component levels is unusual and raises the question of a sample-handling error or a very rare functional deficiency.
In lupus specifically, CH50 remains a useful monitoring tool alongside C3 and C4, though research has found that fluctuations in anti-dsDNA antibodies tend to be more sensitive and specific for predicting an upcoming flare.2PubMed. Serological markers of disease activity in systemic lupus erythematosus Newer complement biomarkers, including split products and cell-bound complement activation products, are also being studied as potentially more sensitive alternatives to CH50, C3, and C4 in lupus.10PubMed Central. Complement as a Biomarker for Systemic Lupus Erythematosus For now, though, the classic panel remains widely used because it is well-established and broadly available.
There are also conditions where CH50 does not add much. In hereditary angioedema, a condition caused by deficiency or dysfunction of C1-inhibitor, research found no correlation between CH50 and disease severity scores, even though C4 levels are typically low during attacks.11PubMed. Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema This is a good reminder that CH50 is a broad screening tool, not a precision instrument for every complement-related condition.
Sample Handling Matters More Than You Might Think
One of the underappreciated pitfalls of CH50 testing is how easily results can be thrown off before the lab even runs the assay. Complement proteins are heat-sensitive and degrade over time once blood is drawn. If a sample sits at room temperature for too long, or is not processed and frozen promptly, complement activity drops and the result comes back falsely low. Research investigating preanalytical stability of complement assays has documented that time delays, elevated temperatures, and even the type of anticoagulant used in the collection tube can all reduce measured CH50 and AH50 activity.12Biochemia Medica. Preanalytical classical and alternative complement pathway activity loss
In practice, this means a surprisingly low CH50 result should always be interpreted with a glance at the logistics. Was the sample shipped overnight in a hot truck? Did it sit on the bench for hours before being spun down? If there is any doubt about handling, repeating the test with a properly processed sample is worthwhile before assuming a genuine complement deficiency. Laboratories that run CH50 typically have specific instructions requiring rapid separation and freezing of serum, and deviations from these protocols can produce clinically misleading results.
Complement-Blocking Drugs and Their Effect on CH50
A newer wrinkle in interpreting CH50 is the growing use of complement-blocking medications. Eculizumab, a drug that blocks the complement protein C5, is used to treat conditions like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Because it prevents the downstream cascade from completing, eculizumab drives CH50 to very low or undetectable levels, which is expected and even used as a sign that the drug is working. In patients with neuromyelitis optica spectrum disorder treated with eculizumab, CH50 activity dropped below the detection limit after treatment began, and researchers have proposed using CH50 as a biomarker to monitor whether the drug is maintaining adequate complement blockade.13PubMed Central. CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
Laboratory studies have confirmed this effect at the bench level. When eculizumab was spiked into serum samples at therapeutic concentrations, partial complement blockage was observed in CH50, AH50, and C5 functional assays.14PubMed. The impact of eculizumab on routine complement assays For clinicians, the practical takeaway is simple: if a patient is on a complement inhibitor, their CH50 will be suppressed by design, and that result should not be mistaken for a disease-related deficiency. As more complement-targeted therapies enter clinical use, this is a distinction that will matter more often.
Modern Alternatives to the Traditional Assay
The classic hemolytic assay using sheep red blood cells works, but it is labor-intensive, requires fresh reagents, and can be finicky. Most large commercial labs have moved to automated methods that measure the same underlying function without the red-blood-cell lysis step. Enzyme immunoassays and liposome-based assays can quantify classical pathway activity in a more standardized, higher-throughput format. Comparisons between these newer methods and the traditional CH50 hemolytic assay have found good agreement, with both newer approaches performing equally well as screening tools for routine clinical specimens.15PubMed Central. Comparison of three different methods for measuring classical pathway complement activity
A liposome-based automated system, for instance, showed a strong correlation with the hemolytic test across a range of complement levels.16Clinical Chemistry. Automated homogeneous liposome-based assay system for total complement activity The shift toward these methods is largely a practical one, driven by the difficulty of maintaining standardized sheep red blood cell preparations, rather than any fundamental limitation of the traditional approach. If you see “CH50” or “total complement activity” on your lab report, it may have been measured by any of these methods, but the clinical interpretation remains the same.
When Your Doctor Might Order This Test
CH50 is not part of routine blood work. It tends to be ordered in specific clinical scenarios where complement dysfunction is suspected or needs to be tracked. The most common situations include:
- Suspected lupus or lupus flare monitoring: Alongside C3, C4, and anti-dsDNA antibodies, CH50 helps gauge whether complement is being consumed by immune complex activity.
- Recurrent serious infections: Particularly meningococcal disease or disseminated gonococcal infections at unusual ages or frequencies, which raise suspicion for an inherited complement deficiency.
- Kidney disease with immune features: Glomerulonephritis caused by immune complex deposition often involves complement consumption.
- Unexplained angioedema: When hereditary angioedema is suspected, CH50 may be part of the initial workup, though C4 and C1-inhibitor levels are more informative for that specific diagnosis.
- Monitoring complement-targeted therapy: In patients on eculizumab or similar drugs, CH50 can confirm that the medication is effectively blocking the complement cascade.
If your lab report shows a CH50 value, the reference range printed alongside it will depend on the method your lab uses and the units they report in. There is no single universal cutoff. What matters clinically is whether the value is within your lab’s stated normal range, near zero, or elevated, and how it fits with the rest of the complement panel and your symptoms. A single mildly low or mildly high CH50 in an otherwise healthy person without relevant symptoms is rarely a cause for alarm, and repeat testing under optimal sample conditions is a reasonable first step before pursuing an expensive genetic or immunological workup.
The Difference Between CH50 and AH50
You may see AH50 (or AP50) ordered alongside CH50, and the distinction is straightforward. CH50 screens the classical pathway, which is activated mainly by antibody-antigen complexes. AH50 screens the alternative pathway, which can fire spontaneously against certain microbial surfaces without needing antibodies. The two pathways share the terminal components C5 through C9 but diverge earlier in the cascade. If both CH50 and AH50 are low, the deficiency likely involves one of those shared terminal components. If only CH50 is low and AH50 is normal, the problem sits in the early classical-pathway-specific components like C1, C2, or C4. If only AH50 is low, the issue involves alternative-pathway-specific factors like Factor B or Factor D.
This paired interpretation is one of the most efficient diagnostic shortcuts in complement testing. It can narrow down which specific component is likely missing or depleted, guiding subsequent testing and, in the case of genetic deficiencies, helping predict infection risk and the need for vaccination strategies against encapsulated bacteria like Neisseria meningitidis. The pattern-based approach also makes complement testing less intimidating than it first appears: you do not need to memorize what all nine-plus components do individually, because the CH50/AH50 pair sorts the problem into categories for you.